BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• Genetown

  New England Biolabs, Inc. Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome

  October 15, 2010

   · 

  2 min read
• Drug Development

  Nektar Therapeutics’s NKTR-181, A Mu-Opioid Analgesic With a Novel Molecular Structure, Demonstrates Slower Entry Rate Into the Brain and Reduced CNS Side Effects

  October 15, 2010

   · 

  6 min read
• Business

  Zecotek Photonics Inc. Announces Appointment of New Independent Director Dr. Jalil Ali

  October 15, 2010

   · 

  3 min read
• Pharm Country

  Acorda Therapeutics Announces Data on AMPYRA(R) (dalfampridine) Presented at 26th Congress of European Committee for Treatment and Research in Multiple Sclerosis

  October 15, 2010

   · 

  1 min read
• FDA

  GI Dynamics Receives European CE Mark Approval for 12 Months of EndoBarrier(TM) Treatment of Type 2 Diabetes and Obesity; Announces U.K. Launch

  October 15, 2010

   · 

  5 min read
• Lone Star Bio

  On-X Life Technologies, Inc. Appoints Senko Exclusive Distributor of the On-X Heart Valve in Japan

  October 15, 2010

   · 

  1 min read
• Drug Development

  Inhibitex, Inc. Completes Enrollment in Phase II Clinical Trial of FV-100 in Shingles Patients

  October 15, 2010

   · 

  1 min read
• Edimer Pharmaceuticals Presents EDI200 Update to International Gathering of Ectodermal Dysplasia Patient Foundations

  October 15, 2010

   · 

  1 min read
• Cardiomyocyte-specific MicroRNA Presents Diagnostic Potential for CV Disorders

  October 15, 2010

   · 

  1 min read
• Drug Development

  Allon Therapeutics, Inc. Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the European Commission (EC)

  October 15, 2010

   · 

  1 min read